UnitedHealthcare Expands Multiple Genetic and Molecular Policies
UnitedHealthcare (UHC) Community Plan’s August policy update revised several medical policies to reflect phase 2 of the DEX® Z-Code requirement for...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
CMS Launches IDR Gateway: What Providers Need to Know Before September 15
In late 2026, the Federal Independent Dispute Resolution (IDR) process will transition from single-use web forms to the new IDR Gateway, which will...
Organizations Representing Clinical Labs and Diagnostics Write in Support of Legislation to Improve Medicare LCD Process
A coalition of more than 30 stakeholder organizations has written to key lawmakers expressing their support for the Timely Access to Coverage...